TCRX
Tscan Therapeutics Inc
0.3205$
+0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -100.0% | – | +174.1% | +155.0% | +40.5% | -15.3% | +18.3% | +5.9% | +34.3% | -17.1% | -8.0% | +119.8% | -53.7% | +23.5% | +85.5% | -92.2% | -5.3% | +95.7% | -36.6% | +226.5% | +41.7% | -18.4% | +2.2% | -61.7% | +7.0% | – | |
| – | +4.7% | +29.1% | +2.6% | +23.1% | +47.2% | +31.5% | -11.2% | +16.5% | -1.3% | -91.4% | +18.6% | +1.0% | -13.5% | -0.8% | -0.5% | -2.0% | -11.0% | -8.0% | -30.8% | – | – | – | -5.7% | -4.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -52.1% | +322.3% | -53.7% | +23.5% | +52.6% | -90.5% | -5.3% | +95.7% | -36.6% | +226.5% | +41.7% | -18.4% | +2.2% | -88.7% | +263.7% | – | |
| – | +4.7% | +29.1% | +2.6% | +23.1% | +47.2% | +31.5% | -11.2% | +16.5% | -1.3% | +3.7% | +3.8% | +39.6% | -2.5% | +7.1% | -1.5% | +10.9% | +8.1% | -2.3% | +11.8% | +1.5% | +9.6% | -2.9% | -36.8% | +9.3% | +6.8% | – | |
| – | -16.7% | +47.9% | +60.3% | -1.3% | +4.6% | +48.5% | +9.9% | +1.0% | +7.0% | +2.1% | +25.1% | +26.5% | -15.9% | -9.8% | +4.5% | +12.0% | +10.0% | -2.4% | -1.5% | +15.9% | +5.5% | -13.7% | -25.6% | +43.4% | -0.9% | – | |
| – | -16.7% | +47.9% | +60.3% | -1.3% | +4.6% | +48.5% | +9.9% | +1.0% | +7.0% | +314.7% | +1.6% | +45.8% | -6.1% | +3.2% | -4.7% | +17.0% | +8.5% | -2.8% | +11.0% | +2.8% | +8.6% | -5.2% | -33.2% | +11.4% | +7.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +250.0% | +2,028.6% | +34.9% | +385.1% | -1.9% | +1.4% | +1.3% | -13.2% | +12.6% | -0.7% | +0.6% | -18.2% | -13.4% | +1.5% | +1.5% | +0.4% | -1.9% | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -86.1% | +1,378.9% | +40.2% | -183.8% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.